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2-Deoxy-2-[18F]fluoro-D-glucose PET/CT is a well-established imaging method for staging,
restaging and therapy-control in human medicine. In veterinary medicine, this imaging
method could prove to be an attractive and innovative alternative to conventional imaging in
order to improve staging and restaging. The aim of this study was both to evaluate the effec-
tiveness of this image-guided method in canine patients with spontaneously occurring can-
cer as well as to illustrate the dog as a well-suited animal model for comparative oncology.
Methods
Ten dogs with various malignant tumors were included in the study and underwent a whole
body FDG PET/CT. One patient has a second PET-CT 5 months after the first study. Pa-
tients were diagnosed with histiocytic sarcoma (n = 1), malignant lymphoma (n = 2), mam-
mary carcinoma (n = 4), sertoli cell tumor (n = 1), gastrointestinal stromal tumor (GIST) (n =
1) and lung tumor (n = 1). PET/CT data were analyzed with the help of a 5-point scale in
consideration of the patients’medical histories.
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Results
In seven of the ten dogs, the treatment protocol and prognosis were significantly changed
due to the results of FDG PET/CT. In the patients with lymphoma (n = 2) tumor extent could
be defined on PET/CT because of increased FDG uptake in multiple lymph nodes. This led
to the recommendation for a therapeutic polychemotherapy as a treatment. In one of the
dogs with mammary carcinoma (n = 4) and in the patient with the lung tumor (n = 1), surgery
was cancelled due to the discovery of multiple metastasis. Consequently no treatment
was recommended.
Conclusion
FDG PET/CT offers additional information in canine patients with malignant disease with a
potential improvement of staging and restaging. The encouraging data of this clinical study
highlights the possibility to further improve innovative diagnostic and staging methods with
regard to comparative oncology. In the future, performing PET/CT not only for staging but
also in therapy control could offer a significant improvement in the management of dogs
with malignant tumors.
Introduction
Cancer is the leading cause of death in dogs as 27% die from malignant tumors [1]. Therefore
one of the main goals in veterinary oncology is improving diagnostic techniques to allow earlier
recognition of tumors in dogs and cats which is essential for successful
therapeutic interventions.
PET/CT is a new attractive method for non-invasive staging, restaging and monitoring of
response to therapy in veterinary medicine. In human medicine, the use of PET/CT was first
described in 2000. Since then, whole body PET/CT in humans has shown to be a useful tool for
diagnosis, staging and monitoring of various malignancies [2–4]. This technique significantly
improves imaging of tumors compared with either PET or CT alone [5,6]. However, the use of
PET/CT in veterinary patients has been limited due to the lack of access to dual-modality hy-
brid PET/CT scanners. The high costs of the equipment and the production of tracers immedi-
ately before their use precluded a widespread use of this technique in veterinary medicine up
to now.
The use of PET/CT in dogs is reported in a number of studies [7–19]. The first use of
FDG-PET in dogs with spontaneously occurring osteosarcoma and lymphoma was described
in 1981. This study demonstrated increased FDG uptake in spontaneous canine malignancies.
Increased FDG uptake was present in both the primary tumors and in metastatic lesions [11].
Whole body PET/CT was performed in healthy dogs to evaluate the physiologic distribution of
FDG in thoracic and abdominal organs, including liver, spleen, adrenal glands and heart mus-
cle [13,18]. These data provide a basis for the interpretation of pathologic changes that can be
imaged by using this technique. Increased uptake of FDG could be demonstrated in canine
lymphoma [11], canine cutaneous mast cell tumor [9], and in various solid tumors (sarcomas,
carcinomas) [15]. In all of these studies, PET seemed to be an efficient and useful tool in canine
patients. This non- invasive diagnostic method allowed imaging of physiologic and pathologic
processes on a molecular level.
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This study was designed by a research cooperation between human and veterinarian insti-
tutes with a keen interest in the improvement of diagnostic and therapeutic methods in com-
parative oncology. The importance of comparative oncology has increased during the last
couple of years. Because of genetic and biologic similarities regarding certain tumor types, the
dog is particularly well suited as a model for human tumors [20]. Using dogs with spontane-
ously arising tumors as a model for human tumors offers advantages over the use of transgenic
animal models due to the more comparable behavior and biologic properties of the tumors.
Therefore, comparative oncology is an important innovative tool that can bridge the gap be-
tween basic cancer research and the clinic with benefits for both human and veterinary medi-
cine [21,22]. Results acquired from pet animals with naturally occurring diseases like
spontaneous tumors can improve the evaluation of the effectiveness and safety of new cancer
therapy options for human and animal patients [23,24].
The aims of this pilot study were to evaluate the feasibility and efficacy of whole body FDG
PET/CT for staging and restaging in dogs with various tumor types. Furthermore, this study
should illustrate the canine patient with spontaneously occurring caner as an animal model for
comparative oncology. In addition the study served to establish a basis for further comparative
studies at the participating institutions.
Material and Methods
Ethics Statement
All experiments described in this paper were carried out with the approval of, and in accor-
dance with the recommendations laid down by the “Deutsches Tierschutzgesetz”. These guide-
lines are equivalent to the “Animal Welfare Act”. This study was approved by the Animal
Welfare Officer of the Centre of Preclinical Research, Technische Universität München, where
the anesthesia and the PET/CT scans of the dogs were performed, in addition to the Govern-
ment of Upper Bavaria.
Patient Population
Ten dogs aged 8.75 ± 1.9 y and weighing 25.8 ± 11.3 kg were included in the study. Five of the
dogs were male (one intact and four neutered) and five female (three intact and two spayed).
Breeds included Flat Coated Retriever (n = 2), Golden Retriever (n = 1), Beauceron (n = 1),
Standard Schnauzer (n = 1) and mixed breed dogs (n = 5).
Informed owner’s consent was required for all dogs participating in the study. Exclusion cri-
teria were a concurrent diagnosis of diabetes mellitus, pregnancy, and an anesthetic risk classi-
fication of ASA IV or V. The ASA classification serves to divide the patients into different
groups according to their physical state and so enables the risk of narcosis to be assessed. Class
I-III describes patients ranging from organically healthy, clinically unremarkable to those with
marked organic / clinical alterations. Class IV describes patients with severe organic damage
and poor vital functions. Class V means that there is an acute risk to life with severe organic
damage. The owners of all dogs were advised to avoid vigorous physical activity for their dogs
during 24 hours before the scan to prevent an excessive FDG uptake within the muscle tissue.
In the preliminary assessment, all dogs underwent a physical examination and a one-view
thoracic radiograph in right lateral recumbency. Blood samples were taken and complete blood
counts as well as a plasma biochemistry profile were performed. The blood glucose level in the
canine patients before the scan was 4.85 mmol/l ± 1.3. According to the results of these exami-
nations, the dogs’ anesthetic risks were classified using the ASA classification system. Depend-
ing on size and localization of the tumor, samples for cytological or histopa thologic evaluation
were taken either by fine needle aspiration, by needle core biopsy or by excisional biopsy.
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The patient with the histiocytic sarcoma was the only patient who underwent a PET/CT ex-
amination twice. The reason for this was a restaging or monitoring of the effects of medication.
The prognosis for a histiocytic sarcoma is very poor with a very high risk of metastasization
and relapse. The median survival time is approximately 6 months [25]. There were three
months between the first and second scan and already 5 months since the diagnosis was made.
This is why we believed that a rescan was indicated as improved staging and as a progress
check using PET/CT.
Anesthesia Protocol
Dogs were fasted for at least 12 hours before FDG PET/CT scanning, but had free access to
water. After intravenous catheter placement, the dogs were pre- medicated intravenously (IV)
with butorphanol (0.2mg/kg) (n = 10) or acepromazine (0.2mg/kg) (n = 1). Both anesthetic
agents are known not to influence the blood glucose level negatively [26,27]. The FDG dose
was calculated according to the dosing scheme published by the pediatric task group, European
Society of Nuclear Medicine [28], (dose rate mean: 225.47 ± 80.02 MBq; 6.09 ± 2.16 Ci)
(Table 1). Anesthesia was induced with propofol (4–6 mg/kg) IV; endotracheal intubation was
performed, and anesthesia was maintained with constant rate infusion of propofol (4–6 mg/
kg/h) IV. All dogs were ventilated with 100% oxygen and were infused with lactated Ringer’s
solution (10 ml/kg/h) IV. During anesthesia, heart rate, respiratory rate, peripheral O2







Pre-treatment Time of PET/CT
1 Flat Coated
Retriever
mn 37.6 Histiocytic sarcoma at
phalanx IV of the left hind leg
Surgical resection of the primary
tumor and CCNU 50mg/kg every
3 week








mn 35.5 Laryngeal Lymphoma Surgical resection of the primary
tumor
One month after surgery
4 Mixed breed mn 6.45 Primary lung tumor No pre-treatment After continuous progression
of the mass
5 Mixed breed f 7.8 Mammary adenocarcinoma No pre-treatment After continuous progression
of the mass
6 Mixed breed mn 39 Sertoli cell tumor Surgical resection of the primary
tumor
One month after surgery
7 Standard
Schnauzer
m 18.5 Gastrointestinal stromal
tumor (GIST)
Surgical resection of the primary
tumor and Palladia
Six month after surgery and






mn 37 Restaging patient 1;
histiocytic Sarcoma
See above at patient 1 Second Scan: 5 months after
the first scan
8 Mixed breed fs 27.2 Nasal Lymphoma Surgical resection of the primary
tumor
One month after surgery
9 Mixed breed f 16.5 Mammary adenocarcinoma No pre-treatment After continuous progression
of the mass
10 Beauceron f 31.5 Mammary adenocarcinoma No pre-treatment After continuous progression
of the mass
Personal description and treatment of every patient before PET/CT
Chlorethyl-Cyclohexyl-Nitroso-Urea (CCNU)/ Lomustin.
doi:10.1371/journal.pone.0127800.t001
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saturation, end-tidal CO2-concentration, peak respiration pressure and minute ventilation vol-
ume were continuously monitored as well as the animals warmed with a heatingpad.
PET/CT Acquisition
After induction of anesthesia, dogs were positioned in the scanner in dorsal or ventral recum-
bency depending on the tumor localization.
FDG PET/CT scans were acquired on a Biograph Sensation 64 PET/CT scanner (Siemens
Healthcare). All patients obtained a dedicated CT scan (120 kV, 180 mAs care dose, 0.5 s per
rotation, 5-mm slice thickness, portal venous phase 80 s after the injection of 1.5 ml/kg of intra-
venous iodine containing contrast agent [Imeron 300 mg/ml]). The diagnostic CT scan was ac-
quired for attenuation correction in resting expiratory position. FDG was administered
intravenously to all patients 83.7 ± 12.11 minutes before the PET/CT scan. Emission time was
2 min per bed position, with 5–9 bed positions per patient (head to tail). These combined in-
struments make it possible to perform a PET and CT examination in one and the same scan
within one instrument. The two examinations are made one directly after the other. The images
are combined with the help of integrated software and a merged image is produced. This tech-
nique enables the exposure time to be considerably shortened and the image quality apprecia-
bly improved by only having to position the patients once, adding value to the data evaluation
process.
Image Analysis
The entire rating procedure was performed on a dedicated workstation using software (Syngo
MMWP [workstation] and Syngo TrueD [software]; Siemens Medical Solutions).
CT und PET data were evaluated independently of one another by two specialists. On the
other hand, the combined PET/CT was evaluated with the two of them together and the results
of the individual CT and PET data combined with the clinical preliminary report.
A 5-point scale was used for the interpretation of the FDG-PET scans, CT scans and com-
bined FDG PET/CT scans according to the following criteria: 1 = definitely benign; 2 = probably
benign; 3 = indeterminate; 4 = probably malignant; 5 = definitely malignant. Scores of 1 and 2
were considered as benign lesions, and scores of 4 and 5 were considered as malignant. With a
score of 3, a statement regarding the malignancy of the lesions was not possible. Therefore, the
CT scans were interpreted subjectively regarding morphology, contrast enhancement, distribu-
tion of contrast agent. For interpretation of the PET data, FDG uptake was assessed according
to the standardized uptake value (SUV).
The SUV is a semi-quantitative method of determining the uptake of a tracer in a specific
tissue by using the following calculation:
SUV ¼
Image activity concentration Bq
g
 
 body weight gð Þ
Injected activity ðBqÞ
For further analysis, the maximum SUV was used.
These SUV values as well as the history of each patient were considered for the evaluation of
the imaged structures in combined PET/CT and assigning values within the 5-point scale. The
aim of this evaluation method was to find out whether the additional PET images provide an
advantage in the diagnosis/assessment of anatomic structures.
For the analysis of the PET/CT results of all patients, a total of 89 individual regions were
evaluated using a 5-point scale and included abdominal and thoracic organs, regional and pe-
ripheral lymph nodes, and salivary glands. The conclusion from this evaluation method was
Comparative Oncology FDG PET/CT in Dogs
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that the additional PET data appreciably simplified the subjective assessment of anatomic
structures compared to CT by itself, especially with the abundance of data from a full body
scan. Follow-up studies are necessary in order to prove this statistically.
A Region of Interest (ROI) is a subset of an image in which the data points are sampled for
analysis. In this study, the ROI was defined as the primary tumor, its draining lymph nodes,
any lesions suggestive of metastatic disease, the liver, spleen, thymus, salivary gland, renal cor-
tex, and left ventricular heart muscle. The ROI was placed at a representative, central position
of the relevant organ, filling the anatomically predefined shape of the organ as well as possible
and the SUV value (min, mean and max) were compiled by drawing the ROI within five suc-
cessive axial, dorsal, or sagittal slices. In the same way, the ROI was placed on the primary tu-
mors if still present and other conspicuous structures. With the lymph nodes on the other
hand, because of the partly smaller size, the ROI was placed centrally using an ellipse and in
the same way the min, mean and max values from five successive sections were used for further
assessment. Brain, renal pelvis, lower urinary tract, blood vessels, and gall bladder were not in-
cluded in the evaluation [15].
Whole body images (Fig 1) acquired one hour after FDG injection were reviewed.
Results
Patient characteristics and any treatment given prior to the FDG PET/CT are shown in
Table 1. The treatment protocol was changed significantly in seven out of ten dogs due to the
results of FDG PET/CT. The resulting therapy after FDG PET/CT and the clinical follow up six
months later is shown in Table 2. Presumed areas of malignancy and other structures with in-
creased FDG uptake were found and involved in further data analysis (Table 3). Table 3 shows
the regions with increased FDG uptake and the cytologic or histologic findings in these regions.
In addition, in every patient, the SUV values of selected organs, the main target areas of metas-
tases (lung, liver and spleen), and the lymph nodes as well as the primary tumors were mea-
sured individually (Table 4). These SUVs are in accordance with previously published FDG
PET/CT data in dogs [9,13,15]. Furthermore the SUV in the primary tumors was increased
compared to the physiologic thoracic and abdominal organs (Table 4). As a rule, malignant tu-
mors exhibit an increased SUV value, a cutoff value of>2.5 being described [29]. However, an
increased SUV does not represent a diagnosis and certainly does not make any further elucida-
tion unnecessary. An increased SUV value is an indication of a malignant tumor, but an in-
flammatory process must always be taken into consideration as a differential diagnosis [30].
Fig 1. Overview of thoracic and abdominal organs in a whole body 18F F-fluoro-2-deoxy-D- glucose
(18F-FDG) positron emission tomography/computer tomography (PET/CT) in a patient with
multicentric lymphoma. (A) Coronal contrast enhanced CT; (B) Coronal 18F-FDG PET/CT. Overview of the
thoracic and abdominal organs of a dog with a multicentric lymphoma. The mean SUVs of these organs are
defined in Table 4. The labeled organs are normal with physiological FDG-uptake (see Table 4).
doi:10.1371/journal.pone.0127800.g001
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Table 4 is intended to show that in our study, the primary tumors exhibit an increased SUV
value compared to physiologic tissue and so can be used as a criterion of malignancy.
In 9 of 10 dogs in this study that underwent FDG PET/CT while a primary tumor was pres-
ent, a distinctly increased FDG uptake within the primary tumor could be measured.






Results of PET/CT Therapy after PET/CT Follow up six month after PET/CT
1 Histiocytic sarcoma 351 No evidence of metastases/ no




Well as far as the end of august 2013; at
this point of time relapse of histiocytic
sarcoma was cytologically diagnosed
dorsal on the left metatarsal bones;
curative RTH was performed; after that
CCNU 50mg/m² was started until now;




208 No evidence of metastases/ no
increased uptake in regional
lymph nodes s
Surgical resection of the
primary tumor
She is doing well
3 Laryngeal
Lymphoma
293 Increased FDG uptake in regional




Dead six weeks after PET/CT scan
4 Primary lung tumor 104.8 Increased uptake in the primary
tumor and in another lung lesion
No therapy, because of
the result of FDG PET/
CT; poor prognosis
He is doing well; Restaging with the aid
of X-rays ten months after the PET/CT
scan; the primary lung tumor has
distinctly grown; furthermore the




96.4 No indication of metastases/ no
increased uptake in regional
lymph nodes
Surgical resection of the
primary tumor
She is doing well
6 Sertoli cell tumor 301 No indication of metastases/ no
increased uptake in regional
lymph nodes
No therapy, because of
the result of FDG PET/
CT
He is doing well
7 Gastrointestinal
stromal tumor (GIST)
169 No indication of metastases/ no




the result of FDG PET/
CT





300 No indication of metastases/ no
increased uptake in regional
lymph nodes
No therapy with CCNU,
because no indication of
metastases
See above at patient 1
8 Nasal Lymphoma 226 Increased FDG uptake in regional
and peripheral lymph nodes
curative RTH Multicentric Lymphoma with enlarged
peripheral lymphnodes three months
after PET/CT scan; Prednisolone 2mg/kg




171 No indication of metastases/ no
increased uptake in regional
lymph nodes
Surgical resection of the
primary tumor
She is doing well
10 Mammary
adenocarcinoma
260 Increased uptake in the primary
tumor Increased uptake in
regional and peripheral lymph
nodes as well as in other organs
No therapy because of
the result of FDG PET/
CT; poor prognosis
Euthanasia five months after PET/CT
Results of PET/CT; in every patient the SUVs of the local and regional lymph nodes as well as the main target areas of metastases were measured for
accommodating the prognosis and following therapy individually. Abnormal findings in CT as well as increased FDG uptake were classified with the help
of the 5-point scale.
doi:10.1371/journal.pone.0127800.t002
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The only tumor lacking increased FDG uptake was the grade I cutaneous mast cell tumor in
one of the dogs presented with an additional mammary carcinoma. This patient first presented
with a mammary carcinoma. In the clinical pre-examination for the PET/CT examination, a
mass with the diameter of approximately 0.5 cm could be clearly palpated which however did
not show increased FDG uptake. Nevertheless, the mass was investigated cytologically before





Suspected Patient SUV mean SUV max SD
Right tooth root Inflammation 2 6.09 9.10 1.22





2 1.98 2.97 0.44
Masses on the dorsal
neck
Lymphoma 3 4.87 5.76 6.95 8.44 1.07 1.03
Intramuscular Lymphoma 3 5.82 3.04 3.81 6.97 7.45 6.11 5.44 8.74 1.10 1.25 0.87 1.13
Lnn. Mandibularis Lymphoma 3 2.03 2.06 2.53 2.62 0.32 0.29
Lnn. Retropharyngealis Lymphoma 3 2.37 2.43 3.01 3.84 0.46 0.42




4 6.28 9.40 1.28
Mass in the lung Metastasis of bronchial
adenocarcinoma
4 0.76 1.02 0.16





5 2.75 4.23 0.51
Salivary glands Hypermetabolic
salivary gland
6 12.40 12.38 13.57 13.42 0.79 0.75
Cutis Telogen effluvium 6 5.77 5.40 7.38 6.62 1.10 0.90
Perianal zone Inflammation 6 10.45 16.07 2.01
Mass near left Ln.
inguinalis
Inflammation post OP 6 2.63 3.80 0.56
Lnn. inguinalis Reactive lymph nodes 6 1.16 1.97 1.68 2.57 0.20 0.35
Mass in the Nose
(primary tumor)
Lymphoma (B-cell) 8 9.11 12.86 2.06
Mediastinal masses Lymphoma (B-cell) 8 2.81 9.54 4.96 4.01 13.59 7.18 0.54 1.97 1.17
Lnn. retropharyngealis Lymphoma (B-cell) 8 7.37 2.47 10.86 3.40 1.53 0.47





10 6.92 10.01 1.06





10 3.62 5.20 0.80
Mass in the spleen Metastasis of
mammary carcinoma
10 2.91 3.58 0.31




10 4.37 6.78 0.82
Mass near anus Basalioma 10 2.78 3.08 0.18
Lnn. axillaris Carcinoma Metastasis of
mammary carcinoma
10 3.21 2.12 5.16 3.23 0.51 0.39
Lnn. retropharyngealis Metastasis of
mammary carcinoma
10 1.62 1.95 2.96 2.22 0.30 0.30
Abnormal findings with increased uptake in PET/CT with their cytologic or histologic or differential diagnosis in individual patients.
doi:10.1371/journal.pone.0127800.t003
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the surgical removal of the mammary tumor and was found to be a mast cell tumor. In the sub-
sequent operation, both the mammary tumor and the mast cell tumor were
surgically removed.
There were a few unexpected findings in one of the dogs. The patient with the previously re-
sected sertoli cell tumor showed markedly increased FDG uptake in both salivary glands. The
same dog showed a diffusely increased cutaneous FDG uptake despite the fact that at the time
the FDG PET/CT was performed, the dog did not show any obvious skin changes on physical
examination. Histopathologic examination of the skin revealed a telogene effluvium. Telogen
effluvium is a scalp disorder characterized by the thinning or shedding of hair resulting from
the early entry of hair in the telogen phase (the resting phase of the hair follicle). Emotional or
physiological stress may result in an alteration of the normal hair cycle and cause the disorder.
Telogen hair follicles in the dermis can be associated with an inflammation [31]. However, this
result was not to be connected with the sertoli cell tumor.
No complications such as an anesthesiological incident or an anaphylactic reaction occurred
during FDG PET/CT and all dogs could be discharged three hours after the examination ac-
cording to the radiation protection ordinance (< 14kBq).
Discussion
The aim of this pilot study was to evaluate the feasibility of FDG PET/CT in dogs as well as the
efficacy of whole body FDG PET/CT for staging in a case series of 10 dogs with various tumor
types with a perspective for further consecutive comparative studies. Furthermore, drawing in-
terest in dogs as a well- suited animal model for comparative oncology was another aim of
this study.
Due to a lack of published data for FDG PET/CT imaging in dogs with sertoli cell tumor,
GIST or Basalioma as well as in hypermetabolic salivary gland no direct comparison with other
studies could be made. For this reason, results deriving from human medicine regarding the
detectability of the mentioned tumors as well as others in FDG PET/CT had to be used.
Only the patient with the sertoli cell tumor showed markedly increased FDG uptake in both
salivary glands. An association of these findings with the sertoli cell tumor was considered very
unlikely. Furthermore a human study concluded that a differentiation between benign and ma-
lignant salivary gland tumors is not possible by FDG PET/CT based on an increased FDG up-
take [32]. Therefore, these findings were not included in further treatment decisions for
the dog.
Up to now an increased FDG uptake has been described only in grade II and grade III ca-
nine mast cell tumors [9]. In this study the only tumor lacking increased FDG uptake was a
grade I cutaneous mast cell tumor. Grade I mast cell tumors have not been evaluated by FDG
PET/CT beforehand, therefore it cannot be excluded that the metabolic activity of grade I tu-
mors may be too low to cause an increased FDG uptake. It is also possible that the grade I mast
cell tumor was too small to be detectable by CT or PET.
In the present study, FDG PET/CT was a particularly promising imaging method in patients
with lymphoma (n = 2) (Fig 2), mammary carcinoma (n = 4) (Fig 3), and primary lung tumor
(n = 1). In these patients the results of FDG PET/CT had a major impact on treatment recom-
mendation. The two dogs with lymphoma were initially considered to suffer from a locally con-
fined tumor. In both patients a systemic involvement could be demonstrated by FDG PET/CT.
Systemic chemotherapy might have resulted in improved survival times in these patients but it
was declined by the owners. In human medicine, FDG PET/CT is already widely used as a
non-invasive method for staging and control of response to treatment in patients with Non-
Hodgkin’s lymphoma [33–36]. In veterinary patients, this method proved to be highly sensitive
Comparative Oncology FDG PET/CT in Dogs
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[9,11,19]. In this study, PET/CT resulted in a significant change in the prognosis and in thera-
peutic recommendations for the lymphoma patients and is expected to be particularly benefi-
cial in these patients to exclude or to detect systemic disease. For further studies it would be
interesting to use 3`-deoxy-3`-[18F]fluoro-thymidine (FLT) tracer instead of FDG as it showed
a higher sensitivity in detecting lymphoma in different species [19,37,38].
In dogs with mammary carcinoma, FDG PET/CT was very helpful for evaluation of regional
lymph nodes in order to confirm or exclude metastatic disease (Fig 4). The exact evaluation of
lymph nodes for metastases before surgery is beneficial for accurate planning of a minimally
invasive surgical procedure. Combined PET/CT has proven to provide considerably more in-
formation on whether lymph node metastases are present or absent compared to CT imaging
alone [39,40]. The results of our study are consistent with this statement. We wanted to show
with our study that the analysis of CT data can be simplified greatly with the aid of PET. Tra-
cheobronchial lymph nodes and abdominal abdominal lymph nodes, in particular, are visual-
ized more clearly by combined PET/CT than CT alone. This facilitates the evaluation of
possible pathological findings at these locations. Abnormalities of internal organs are also bet-
ter visualized with PET, making it easier to evaluate changes here as well. (Fig 3).
In addition, FDG and FLT PET/CT were described in a dog with a primary bronchial ade-
nocarcinoma [8]. In that case report, the dog was evaluated with PET/CT before and after
Table 4. SUVmax values in organs.
Organ N Minimum Maximum Mean SD
Liver 10 1.71 3.39 2.6480 .60716
Spleen 10 1.33 2.51 1.9210 .43370
Myocardium 10 1.63 5.78 3.4790 1.35948
Cortex of kidney 10 2.49 5.41 3.8730 1.05205
Salivary gland 9 2.18 6.66 4.6572 1.44825
Lymph nodes 10 1.36 4.70 2.0303 .97479
Primary tumor 6 2.97 12.86 7.7367 3.73684
Solid metastases 4 1.02 8.62 5.656 3.275
Lymph node metastases 3 3.0 4.54 3.9 .77485
Primary tumor measured in patient numbers 2,4,5,8,9,10.
Solid and lymph node (suspected) metastases are defined separately in table.
doi:10.1371/journal.pone.0127800.t004
Fig 2. 18F-FDG uptake in a patient with multicentric lymphoma. (A) Coronal contrast enhanced computer
tomography (CT); (B) Coronal 18F-fluoro-2-deoxy-D- glucose (18F-FDG positron emission tomography
(PET)/CT) Increased FDG uptake in both retropharyngales lymph nodes (standardized uptake value (SUV)
mean 2.37 and 2.43 ± 2.4) as well as intramuscular increased FDG-uptake (SUVmean 3.04 ± 1.25).
doi:10.1371/journal.pone.0127800.g002
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treatment. Both FDG and FLT PET/CT tracers were found to be effective in differentiating
tumor tissue from physiologic or reactive tissue. In the present study, FDG PET/CT was also
used in a dog with a primary pulmonary tumor. On PET/CT, pulmonary metastatic disease
was found, whereas no increased FDG uptake could be demonstrated within the locally drain-
ing lymph nodes. In human as well as in veterinary medicine the staging, especially the medias-
tinal nodal staging, is the most important prognostic factor concerning the median survival
time in patients with primary pulmonary carcinoma [41–43]. This finding led to the decision
against surgical treatment (e.g. lung lobectomy) despite the lack of mediastinal lymph node
metastases. The relatively low FDG uptake in the metastatic lung lesion (SUV max 1.02 ± 0.16)
compared to the primary tumor (SUV max 9.40 ± 1.28) is characteristic for human lung cancer
[44]. Even though PET/CT is more accurate in detecting metastases compared to CT alone
[45], false- positive findings in PET/CT have to be considered [46]. In this study, the lung le-
sion (left pulmonary lobe, pars cranialis, dorsally, marginally, about 0.6mm diameter) could be
confirmed by X-rays during restaging six months later which proved the PET/CT findings.
In dogs with histiocytic sarcoma (n = 1), sertoli cell tumor (n = 1) and GIST (n = 1), FDG
PET/CT showed no indications of metastases although the histologic findings as well as the bi-
ologic behavior of the tumor predicted a poor prognosis. Therefore, the follow up treatment
was not changed. In human patients with GIST, FDG PET/CT is already widely used for non-
invasive staging. A correlation between the degree of malignancy and the intensity of FDG up-
take has been demonstrated, so FDG PET/CT provides important prognostic information in
Fig 3. 18F F-fluoro-2-deoxy-D-glucose (18F-FDG) uptake in a patient with mammary carcinoma and
multiple metastases. (A) Axial contrast enhanced computer tomography (CT); (B) Axial 18F-FDG positron
emission tomography (PET)/CT Increased FDG uptake in the primary tumor (SUVmean 6.92 ± 1.06),
histologically a mammary carcinoma on the mammary gland; hepatomegaly; mass within the spleen with
increased 18F- FDG uptake (SUV mean 2.91 ± 0.31).
doi:10.1371/journal.pone.0127800.g003
Fig 4. 18F F-fluoro-2-deoxy-D-glucose (18F-FDG) uptake in a patient with mammary carcinoma and
multiple metastases. (A) Coronal contrast enhanced computer tomography (CT); (B) Coronal 18F-FDG
positron emission tomography (PET)/CT Increased FDG uptake in both lnn. axillares (SUVmean 2.67 ± 0.77)
as well as in a subcutaneous mass (the more caudally located structure) (SUVmean 4.37 ± 0.82).
doi:10.1371/journal.pone.0127800.g004
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this tumor type. FDG PET/CT has also proven to be helpful for evaluation of the response to
treatment and early recognition of tumor recurrence in patients with GIST [47–49]. However,
FDG uptake in human GISTs was reported to vary widely [50]. Negative, low, or intensive
FDG uptake can occur. In the present study, FDG PET/CT was performed in the patient after
surgical resection of a GIST. Therefore, a comparison with pre-treatment values was not possi-
ble, nor was evaluation of the primary tumor possible.
In human medicine, there are only a small number of reports on FDG PET/CT in patients
with a Sertoli cell tumor [51] or histiocytic sarcoma. Increased uptake was reported to be mea-
sured in the mass themselves as well as in metastatic lymph nodes [52]. In addition there is one
case report with a FDG PET in a canine intracranial histiocytic sarcoma [16]. These case re-
ports indicate that FDG PET/CT might be valuable for early detection and staging of testicular
tumors and histiocytic sarcoma in human as well as in veterinary medicine.
These cases should illustrate the possible consequences of staging by FDG PET/CT in canine
patients as well as the comparable and transferable results in human and veterinarian patients
with spontaneously occurring cancer.
Limitations of the study are the small number of patients that precluded statistical evaluation
of the results and the heterogeneous patient population including various tumor types and dogs
with and without prior treatment of their tumors which precluded a direct comparison with
other imaging methods for staging. Some dogs underwent surgical resection of their primary
tumor before FDG PET/CT. In these cases, FDG PET/CT evaluation of the primary tumor was
not possible. In patients with incompletely resected primary tumors, the FDG uptake at the site
of surgery might have been compromised by physiologic postoperative local reactions.
Conclusion
In conclusion, the results of this pilot study indicate that FDG PET/CT in dogs with previously
described malignancies can be a promising technique for the staging of dogs with specific can-
cers and a very useful tool for individual adaptation of treatment and prognosis. The interpre-
tation and evaluation of the FDG PET/CT values shows similar advantages and restraints as in
human patients. Thus, it appears to be plausible for the canine tumor patient to be able to serve
as a model for diagnostic and therapeutic studies of human cancer in the future. However, clin-
ical signs of the patient as well as the biologic behavior of various tumor types have to be con-
sidered when interpreting the data obtained by FDG PET/CT. This is required for correct
interpretation of increased FDG uptake and for establishing a correlation with an underlying
disease process. Further studies to evaluate the sensitivity and specificity of this method as well
as the differentiation of more specific tracers for oncologic PET/CT in dogs are necessary. Al-
though the imaging with FDG PET/CT is not a new method in human medicine, this study
should draw interest to dogs as an animal model for further comparative studies.
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